DD283140A5 - Verfahren zur herstellung von therapeutischen heterozyclischen verbindungen - Google Patents
Verfahren zur herstellung von therapeutischen heterozyclischen verbindungen Download PDFInfo
- Publication number
- DD283140A5 DD283140A5 DD88320940A DD32094088A DD283140A5 DD 283140 A5 DD283140 A5 DD 283140A5 DD 88320940 A DD88320940 A DD 88320940A DD 32094088 A DD32094088 A DD 32094088A DD 283140 A5 DD283140 A5 DD 283140A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- formula
- compound
- group
- defined above
- indol
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 7
- 150000002391 heterocyclic compounds Chemical class 0.000 title claims abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 87
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000012453 solvate Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 171
- -1 xanthenyl Dibenzofuranyl Chemical group 0.000 claims description 39
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical class 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 150000001450 anions Chemical class 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 238000007363 ring formation reaction Methods 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 238000006193 diazotization reaction Methods 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000005239 aroylamino group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 150000008049 diazo compounds Chemical class 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 23
- 238000011282 treatment Methods 0.000 abstract description 16
- 208000019695 Migraine disease Diseases 0.000 abstract description 9
- 206010027599 migraine Diseases 0.000 abstract description 8
- 239000000047 product Substances 0.000 description 72
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 238000007792 addition Methods 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 238000009472 formulation Methods 0.000 description 21
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 13
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 239000000377 silicon dioxide Substances 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 239000003826 tablet Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000012258 stirred mixture Substances 0.000 description 9
- ZRPAIVPIYDTPDO-ODZAUARKSA-N (z)-but-2-enedioic acid;ethanamine Chemical compound CCN.OC(=O)\C=C/C(O)=O ZRPAIVPIYDTPDO-ODZAUARKSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 8
- 239000012346 acetyl chloride Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000556 agonist Substances 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229940069328 povidone Drugs 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 4
- NWLPAIVRIWBEIT-UAIGNFCESA-N (z)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C/C(O)=O NWLPAIVRIWBEIT-UAIGNFCESA-N 0.000 description 3
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 3
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 3
- 238000007126 N-alkylation reaction Methods 0.000 description 3
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006254 arylation reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 229940080313 sodium starch Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 2
- FQBLFAXFYIRSFS-UAIGNFCESA-N (z)-but-2-enedioic acid;ethanamine;hydrate Chemical compound O.CCN.OC(=O)\C=C/C(O)=O FQBLFAXFYIRSFS-UAIGNFCESA-N 0.000 description 2
- HAFWELDDNUXLCK-ODZAUARKSA-N (z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O HAFWELDDNUXLCK-ODZAUARKSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- XBAJPXWNHOKEIF-UHFFFAOYSA-N 1-[(4-aminophenyl)methyl]-3-benzylimidazolidin-2-one;hydrochloride Chemical compound Cl.C1=CC(N)=CC=C1CN1C(=O)N(CC=2C=CC=CC=2)CC1 XBAJPXWNHOKEIF-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
- WHWSLTIMWRMKID-UHFFFAOYSA-N 3-benzyl-1-[(4-nitrophenyl)methyl]pyrrolidine-2,5-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)C(CC=2C=CC=CC=2)CC1=O WHWSLTIMWRMKID-UHFFFAOYSA-N 0.000 description 2
- RRRHKSDHEJAWOP-UHFFFAOYSA-N 4-[(4-aminophenyl)methyl]-1-benzyl-3-methylimidazolidin-2-one;hydrochloride Chemical compound Cl.C1N(CC=2C=CC=CC=2)C(=O)N(C)C1CC1=CC=C(N)C=C1 RRRHKSDHEJAWOP-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- COZUHTATRBKBAO-UHFFFAOYSA-N 5-[(4-nitrophenyl)methyl]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1C(=O)NC(=O)N1 COZUHTATRBKBAO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 229960001413 acetanilide Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 229960004279 formaldehyde Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000011872 intimate mixture Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- OWIFNISFRBVGIX-UHFFFAOYSA-N (3-phenoxyphenyl)methanamine Chemical compound NCC1=CC=CC(OC=2C=CC=CC=2)=C1 OWIFNISFRBVGIX-UHFFFAOYSA-N 0.000 description 1
- SMIXZZMSWYOQPW-UHFFFAOYSA-N (4-nitrophenyl)methylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=C([N+]([O-])=O)C=C1 SMIXZZMSWYOQPW-UHFFFAOYSA-N 0.000 description 1
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HEFUECJUGNNPMX-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[[4-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]-2,5-dioxoimidazolidin-1-yl]methyl]benzonitrile Chemical compound OC(=O)\C=C/C(O)=O.C1=C2C(CCN(C)C)=CNC2=CC=C1CC(C1=O)NC(=O)N1CC1=CC=C(C#N)C=C1 HEFUECJUGNNPMX-BTJKTKAUSA-N 0.000 description 1
- NTURQZFFJDCTMZ-UHFFFAOYSA-N 1-(2-bromoethyl)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CCBr)C=C1 NTURQZFFJDCTMZ-UHFFFAOYSA-N 0.000 description 1
- IPABSFWQUQNBGI-FJOGWHKWSA-N 1-[[3-(2-aminoethyl)-1h-indol-5-yl]methyl]-4-benzyl-1,2,4-triazolidine-3,5-dione;(z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O.C1=C2C(CCN)=CNC2=CC=C1CN(C1=O)NC(=O)N1CC1=CC=CC=C1 IPABSFWQUQNBGI-FJOGWHKWSA-N 0.000 description 1
- VGSOIJXATRUNDU-UHFFFAOYSA-N 1-benzyl-3-[(4-nitrophenyl)methyl]pyrrolidine-2,5-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1C(=O)N(CC=2C=CC=CC=2)C(=O)C1 VGSOIJXATRUNDU-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- QXHDYMUPPXAMPQ-UHFFFAOYSA-N 2-(4-aminophenyl)ethanol Chemical compound NC1=CC=C(CCO)C=C1 QXHDYMUPPXAMPQ-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- JUHYZGPSJIUDDU-UHFFFAOYSA-N 2-hydroxy-3-(4-nitrophenyl)propanoic acid Chemical compound OC(=O)C(O)CC1=CC=C([N+]([O-])=O)C=C1 JUHYZGPSJIUDDU-UHFFFAOYSA-N 0.000 description 1
- WYPCLKWDXUSOEN-UHFFFAOYSA-N 3-(chloromethyl)-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(CCl)=C1 WYPCLKWDXUSOEN-UHFFFAOYSA-N 0.000 description 1
- YCAIYRWHKSJKEB-UHFFFAOYSA-N 3-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=CC(C(Cl)=O)=C1 YCAIYRWHKSJKEB-UHFFFAOYSA-N 0.000 description 1
- RQUXUQHVECQMKF-UHFFFAOYSA-N 3-[(4-nitrophenyl)methyl]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)NCC1=O RQUXUQHVECQMKF-UHFFFAOYSA-N 0.000 description 1
- DUDGVIIVLLSHGX-UHFFFAOYSA-N 3-[(4-nitrophenyl)methyl]oxolane-2,5-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1C(=O)OC(=O)C1 DUDGVIIVLLSHGX-UHFFFAOYSA-N 0.000 description 1
- JJHSMSSQEZNLDU-BTJKTKAUSA-N 3-[[3-(2-aminoethyl)-1h-indol-5-yl]methyl]-5-(thiophen-2-ylmethyl)imidazolidine-2,4-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=C2C(CCN)=CNC2=CC=C1CN(C1=O)C(=O)NC1CC1=CC=CS1 JJHSMSSQEZNLDU-BTJKTKAUSA-N 0.000 description 1
- SUGKTPOCDASYEO-BTJKTKAUSA-N 3-[[3-(2-aminoethyl)-1h-indol-5-yl]methyl]-5-benzylimidazolidine-2,4-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=C2C(CCN)=CNC2=CC=C1CN(C1=O)C(=O)NC1CC1=CC=CC=C1 SUGKTPOCDASYEO-BTJKTKAUSA-N 0.000 description 1
- DLJPKKFSMLUXJH-UHFFFAOYSA-N 3-[[4-[(4-aminophenyl)methyl]-2,5-dioxoimidazolidin-1-yl]methyl]-n-methylbenzamide;hydrochloride Chemical compound Cl.CNC(=O)C1=CC=CC(CN2C(C(CC=3C=CC(N)=CC=3)NC2=O)=O)=C1 DLJPKKFSMLUXJH-UHFFFAOYSA-N 0.000 description 1
- UJOYFRCOTPUKAK-UHFFFAOYSA-N 3-ammonio-3-phenylpropanoate Chemical compound [O-]C(=O)CC([NH3+])C1=CC=CC=C1 UJOYFRCOTPUKAK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- TWWPYOQJKFJOEA-UHFFFAOYSA-N 3-benzyl-1-[(4-nitrophenyl)methyl]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)N(CC=2C=CC=CC=2)C(=O)C1 TWWPYOQJKFJOEA-UHFFFAOYSA-N 0.000 description 1
- RVXZLSBXFXELRB-UHFFFAOYSA-N 3-benzyl-5-[(4-nitrophenyl)methyl]-1,3-oxazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1C(=O)N(CC=2C=CC=CC=2)C(=O)O1 RVXZLSBXFXELRB-UHFFFAOYSA-N 0.000 description 1
- IVMNRYKNOBFVIQ-UHFFFAOYSA-N 3-benzyl-5-[(4-nitrophenyl)methyl]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1C(=O)N(CC=2C=CC=CC=2)C(=O)N1 IVMNRYKNOBFVIQ-UHFFFAOYSA-N 0.000 description 1
- GEBDBHGZJXMMAL-BTJKTKAUSA-N 3-benzyl-5-[2-[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]ethyl]imidazolidine-2,4-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=C2C(CCN(C)C)=CNC2=CC=C1CCC(C1=O)NC(=O)N1CC1=CC=CC=C1 GEBDBHGZJXMMAL-BTJKTKAUSA-N 0.000 description 1
- AODAEDMAPRQATI-UHFFFAOYSA-N 3-benzylimidazolidine-2,4-dione Chemical compound O=C1CNC(=O)N1CC1=CC=CC=C1 AODAEDMAPRQATI-UHFFFAOYSA-N 0.000 description 1
- OOEHLTSDDZKTQB-UHFFFAOYSA-N 3-benzyloxolane-2,5-dione Chemical compound O=C1OC(=O)CC1CC1=CC=CC=C1 OOEHLTSDDZKTQB-UHFFFAOYSA-N 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- NXTDJHZGHOFSQG-UHFFFAOYSA-N 3-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OC=2C=CC=CC=2)=C1 NXTDJHZGHOFSQG-UHFFFAOYSA-N 0.000 description 1
- MJLDEUZMYDEJNJ-FJOGWHKWSA-N 4-[[4-[[3-(2-aminoethyl)-1h-indol-5-yl]methyl]-2,5-dioxoimidazolidin-1-yl]methyl]benzonitrile;(z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O.C1=C2C(CCN)=CNC2=CC=C1CC(C1=O)NC(=O)N1CC1=CC=C(C#N)C=C1 MJLDEUZMYDEJNJ-FJOGWHKWSA-N 0.000 description 1
- AHSGRQNZXBIREA-UHFFFAOYSA-N 4-benzyl-1,2,4-triazolidine-3,5-dione Chemical compound O=C1NNC(=O)N1CC1=CC=CC=C1 AHSGRQNZXBIREA-UHFFFAOYSA-N 0.000 description 1
- UEWOCUYGFXQJLO-UHFFFAOYSA-N 4-benzyl-1-[(4-nitrophenyl)methyl]-1,2,4-triazolidine-3,5-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)N(CC=2C=CC=CC=2)C(=O)N1 UEWOCUYGFXQJLO-UHFFFAOYSA-N 0.000 description 1
- LTLKJYMNUSSFAH-UHFFFAOYSA-N 4-chloro-1,1-dimethoxybutane Chemical compound COC(OC)CCCCl LTLKJYMNUSSFAH-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- MPKSCRDPCMQDHL-BTJKTKAUSA-N 5-[2-[3-(2-aminoethyl)-1h-indol-5-yl]ethyl]-3-benzylimidazolidine-2,4-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=C2C(CCN)=CNC2=CC=C1CCC(C1=O)NC(=O)N1CC1=CC=CC=C1 MPKSCRDPCMQDHL-BTJKTKAUSA-N 0.000 description 1
- SDMLALSERIWKPW-BTJKTKAUSA-N 5-[[3-(2-aminoethyl)-1h-indol-5-yl]methyl]-3-(3-phenylpropyl)imidazolidine-2,4-dione;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1=C2C(CCN)=CNC2=CC=C1CC(C1=O)NC(=O)N1CCCC1=CC=CC=C1 SDMLALSERIWKPW-BTJKTKAUSA-N 0.000 description 1
- VOQIIRVHFQRKTO-FJOGWHKWSA-N 5-[[3-(2-aminoethyl)-1h-indol-5-yl]methyl]-3-benzyl-1,3-oxazolidine-2,4-dione;(z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O.C1=C2C(CCN)=CNC2=CC=C1CC(C1=O)OC(=O)N1CC1=CC=CC=C1 VOQIIRVHFQRKTO-FJOGWHKWSA-N 0.000 description 1
- XUGFSXSNNYLBPL-UHFFFAOYSA-N 5-benzyl-3-[2-(4-nitrophenyl)ethyl]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCN1C(=O)C(CC=2C=CC=CC=2)NC1=O XUGFSXSNNYLBPL-UHFFFAOYSA-N 0.000 description 1
- DBOMTIHROGSFTI-UHFFFAOYSA-N 5-benzylimidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1CC1=CC=CC=C1 DBOMTIHROGSFTI-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- NKCNKDJJGHVLKK-UHFFFAOYSA-N C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)N(CC=2C=C(OC=3C=CC=CC=3)C=CC=2)C(=O)C1 Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C(=O)N(CC=2C=C(OC=3C=CC=CC=3)C=CC=2)C(=O)C1 NKCNKDJJGHVLKK-UHFFFAOYSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000006906 Vascular Ring Diseases 0.000 description 1
- BTHMRXRBXYHLRA-UHFFFAOYSA-N [1-methoxy-3-(4-nitrophenyl)-1-oxopropan-2-yl]azanium;chloride Chemical compound Cl.COC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 BTHMRXRBXYHLRA-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Chemical group 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 1
- JZJPBADSXBZWAZ-UHFFFAOYSA-N diethyl 2-benzylbutanedioate Chemical compound CCOC(=O)CC(C(=O)OCC)CC1=CC=CC=C1 JZJPBADSXBZWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007904 elastic gelatin capsule Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MQZXMVGZGJXQOB-UHFFFAOYSA-N methyl 2-hydroxy-3-(4-nitrophenyl)propanoate Chemical compound COC(=O)C(O)CC1=CC=C([N+]([O-])=O)C=C1 MQZXMVGZGJXQOB-UHFFFAOYSA-N 0.000 description 1
- JMCKNKWCFXTYTJ-UHFFFAOYSA-N methyl 3-(4-nitrophenyl)-2-[(3-phenoxyphenyl)methylcarbamoylamino]propanoate Chemical compound C=1C=CC(OC=2C=CC=CC=2)=CC=1CNC(=O)NC(C(=O)OC)CC1=CC=C([N+]([O-])=O)C=C1 JMCKNKWCFXTYTJ-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- IFGRJIRFNLSHER-UHFFFAOYSA-N n-[2-[[4-[[3-(2-aminoethyl)-1h-indol-5-yl]methyl]-2,5-dioxoimidazolidin-1-yl]methyl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1CN1C(=O)C(CC=2C=C3C(CCN)=CNC3=CC=2)NC1=O IFGRJIRFNLSHER-UHFFFAOYSA-N 0.000 description 1
- VYEJXTZQKRHBHH-UHFFFAOYSA-N n-[4-(2-hydroxyethyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(CCO)C=C1 VYEJXTZQKRHBHH-UHFFFAOYSA-N 0.000 description 1
- UNQRTKYIKWZIKR-UHFFFAOYSA-N n-methyl-3-[[4-[(4-nitrophenyl)methyl]-2,5-dioxoimidazolidin-1-yl]methyl]benzamide Chemical compound CNC(=O)C1=CC=CC(CN2C(C(CC=3C=CC(=CC=3)[N+]([O-])=O)NC2=O)=O)=C1 UNQRTKYIKWZIKR-UHFFFAOYSA-N 0.000 description 1
- SQEXOCHJRREZAP-UHFFFAOYSA-N n-methyl-3-[[4-[[3-[2-(methylamino)ethyl]-1h-indol-5-yl]methyl]-2,5-dioxoimidazolidin-1-yl]methyl]benzamide Chemical compound C1=C2C(CCNC)=CNC2=CC=C1CC(C1=O)NC(=O)N1CC1=CC=CC(C(=O)NC)=C1 SQEXOCHJRREZAP-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- RPNRGCZUORVKJF-UHFFFAOYSA-N triethyl 1-benzylethane-1,1,2-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(C(=O)OCC)CC1=CC=CC=C1 RPNRGCZUORVKJF-UHFFFAOYSA-N 0.000 description 1
- TVWZLLYAJDSSCJ-UHFFFAOYSA-N triethyl ethane-1,1,2-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)C(=O)OCC TVWZLLYAJDSSCJ-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878724912A GB8724912D0 (en) | 1987-10-23 | 1987-10-23 | Indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD283140A5 true DD283140A5 (de) | 1990-10-03 |
Family
ID=10625806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD88320940A DD283140A5 (de) | 1987-10-23 | 1988-10-21 | Verfahren zur herstellung von therapeutischen heterozyclischen verbindungen |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0313397B1 (fr) |
| JP (1) | JP2501631B2 (fr) |
| CN (1) | CN1035113A (fr) |
| AT (1) | ATE90089T1 (fr) |
| AU (1) | AU604165B2 (fr) |
| DD (1) | DD283140A5 (fr) |
| DE (1) | DE3881472T2 (fr) |
| DK (1) | DK586588A (fr) |
| ES (1) | ES2054825T3 (fr) |
| FI (1) | FI884879A7 (fr) |
| GB (1) | GB8724912D0 (fr) |
| HU (1) | HU202230B (fr) |
| IL (1) | IL88122A0 (fr) |
| MC (1) | MC1983A1 (fr) |
| NZ (1) | NZ226671A (fr) |
| PL (1) | PL158305B1 (fr) |
| PT (1) | PT88829B (fr) |
| ZA (1) | ZA887900B (fr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT95899A (pt) * | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
| IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
| PT97888B (pt) | 1990-06-07 | 1998-12-31 | Zeneca Ltd | Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem |
| EP0494774A1 (fr) * | 1991-01-11 | 1992-07-15 | MERCK SHARP & DOHME LTD. | Composés hétéroaromatiques à 5 chaînons substitués par l'indazole |
| US5317103A (en) * | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
| CZ283018B6 (cs) * | 1991-02-01 | 1997-12-17 | Merck Sharp And Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi |
| TW263508B (fr) * | 1991-02-12 | 1995-11-21 | Pfizer | |
| GB9104136D0 (en) * | 1991-02-27 | 1991-04-17 | Merck Sharp & Dohme | Therapeutic agents |
| HUT69705A (en) * | 1991-11-25 | 1995-09-28 | Pfizer | Indole derivatives |
| CA2083891A1 (fr) * | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Composes heterocycliques, compositions et utilisation therapeutique |
| US5409941A (en) * | 1992-02-03 | 1995-04-25 | Pfizer Inc. | 5-heteroyl indole derivatives |
| TW288010B (fr) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| ATE205202T1 (de) * | 1992-03-13 | 2001-09-15 | Merck Sharp & Dohme | Imidazol-, triazol- und tetrazolderivate |
| GB9207396D0 (en) * | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| US5747501A (en) | 1992-04-07 | 1998-05-05 | Pfizer, Inc. | Indole derivatives |
| US6380233B1 (en) | 1992-04-07 | 2002-04-30 | Pfizer Inc | Indole derivatives as 5-HT1 agonists |
| GB9207930D0 (en) * | 1992-04-10 | 1992-05-27 | Pfizer Ltd | Indoles |
| NZ251047A (en) * | 1992-04-10 | 1996-09-25 | Pfizer | Acylaminoindole derivatives and medicaments |
| GB9208463D0 (en) * | 1992-04-16 | 1992-06-03 | Merck Sharp & Dohme | Therapeutic agents |
| GB9210400D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
| GB9211277D0 (en) | 1992-05-28 | 1992-07-15 | Glaxo Group Inc | Pharmaceutical compositions |
| DE69318212T2 (de) * | 1992-06-05 | 1998-11-19 | Merck Sharp & Dohme | Sulfatsalz von einem substituierten Triazol, seine pharmazeutischen Zusammensetzungen und ihre Verwendung in Therapie |
| GB9215526D0 (en) * | 1992-07-22 | 1992-09-02 | Merck Sharp & Dohme | Chemical process |
| JPH07509452A (ja) * | 1992-07-24 | 1995-10-19 | メルク シヤープ エンド ドーム リミテツド | イミダゾール，トリアゾール及びテトラゾール誘導体 |
| IL106445A (en) * | 1992-07-30 | 1998-01-04 | Merck Sharp & Dohme | History of 1,2,4-Trans-Triazole 4-Transform, Preparation and Pharmaceutical Preparations Containing Them |
| TW251284B (fr) * | 1992-11-02 | 1995-07-11 | Pfizer | |
| GB9226537D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
| LT3594B (en) | 1993-07-29 | 1995-12-27 | Merck Sharp & Dohme | Imidazole,triazole and tetrazole derivatives |
| ES2070087B1 (es) * | 1993-08-13 | 1996-02-16 | Pfizer | Derivados de indol |
| US6423731B2 (en) | 1994-01-06 | 2002-07-23 | Zeneca Limited | Indole derivatives as prodrugs of 5-HT1-like receptor agonists |
| GB9401436D0 (en) * | 1994-01-26 | 1994-03-23 | Wellcome Found | Therapeutic heterocyclic compounds |
| GB9407447D0 (en) * | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| DE69521895T2 (de) * | 1994-06-01 | 2002-04-04 | Astrazeneca Ab, Soedertaelje | Indolderivate als prodrugs von "5-ht1-like" rezeptor agonisten |
| FI970310L (fi) * | 1994-07-26 | 1997-01-24 | Pfizer | 4-indolijohdannaiset serotoniinin vaikuttaja- ja vastavaikuttaja-aineina |
| US6025374A (en) * | 1994-12-06 | 2000-02-15 | Merck Sharp & Dohme, Ltd. | Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists |
| GB9516145D0 (en) * | 1995-08-07 | 1995-10-04 | Wellcome Found | Improved chemical synthesis |
| US6909005B1 (en) | 1995-08-07 | 2005-06-21 | Astrazeneca Uk Limited | One post synthesis of 2-oxazolidinone derivatives |
| GB9516143D0 (en) | 1995-08-07 | 1995-10-04 | Wellcome Found | Improved chemical synthesis |
| US5998438A (en) * | 1996-11-26 | 1999-12-07 | Allelix Biopharmaceuticals, Inc. | 5-cyclo indole compounds |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| WO2000000490A2 (fr) * | 1998-06-26 | 2000-01-06 | Eli Lilly And Company | Agonistes de 5-ht¿1f? |
| DE60329607D1 (de) | 2002-06-21 | 2009-11-19 | Suven Life Sciences Ltd | Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten |
| DK1523486T3 (da) | 2002-06-21 | 2008-03-03 | Suven Life Sciences Ltd | Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet |
| JP4559230B2 (ja) | 2002-11-28 | 2010-10-06 | スベン ライフ サイエンシズ リミティド | セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物 |
| MXPA05005700A (es) | 2002-11-28 | 2005-08-16 | Suven Life Sciences Ltd | N-arilsulfonil-3-aminoalcoxiindoles. |
| EA009367B1 (ru) | 2002-12-18 | 2007-12-28 | Сувен Лайф Сайенсиз Лимитед | ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА |
| DE102005018191A1 (de) * | 2005-04-19 | 2006-10-26 | Grünenthal GmbH | Substituierte zyklische Harnstoff-Derivate und deren Verwendung zur Herstellung von Arzneimitteln |
| WO2017130141A1 (fr) | 2016-01-27 | 2017-08-03 | Instar Technologies A.S. | Supports nanofibreux oromumuqueux pour traitement thérapeutique |
| CN112759550A (zh) * | 2019-11-04 | 2021-05-07 | 上海科技大学 | 一种平滑受体拮抗剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833153A (en) | 1985-11-08 | 1989-05-23 | Glaxo Group Limited | Indole derivatives |
| GB8600397D0 (en) | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
-
1987
- 1987-10-23 GB GB878724912A patent/GB8724912D0/en active Pending
-
1988
- 1988-10-21 FI FI884879A patent/FI884879A7/fi not_active Application Discontinuation
- 1988-10-21 AT AT88309943T patent/ATE90089T1/de not_active IP Right Cessation
- 1988-10-21 DE DE88309943T patent/DE3881472T2/de not_active Expired - Fee Related
- 1988-10-21 JP JP63265917A patent/JP2501631B2/ja not_active Expired - Lifetime
- 1988-10-21 PT PT88829A patent/PT88829B/pt not_active IP Right Cessation
- 1988-10-21 ZA ZA887900A patent/ZA887900B/xx unknown
- 1988-10-21 DK DK586588A patent/DK586588A/da not_active Application Discontinuation
- 1988-10-21 CN CN88108816A patent/CN1035113A/zh active Pending
- 1988-10-21 PL PL1988275423A patent/PL158305B1/pl unknown
- 1988-10-21 IL IL88122A patent/IL88122A0/xx unknown
- 1988-10-21 DD DD88320940A patent/DD283140A5/de not_active IP Right Cessation
- 1988-10-21 NZ NZ226671A patent/NZ226671A/xx unknown
- 1988-10-21 MC MC882012A patent/MC1983A1/fr unknown
- 1988-10-21 EP EP88309943A patent/EP0313397B1/fr not_active Expired - Lifetime
- 1988-10-21 HU HU885431A patent/HU202230B/hu unknown
- 1988-10-21 ES ES88309943T patent/ES2054825T3/es not_active Expired - Lifetime
- 1988-10-24 AU AU24181/88A patent/AU604165B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0313397B1 (fr) | 1993-06-02 |
| NZ226671A (en) | 1991-09-25 |
| FI884879A0 (fi) | 1988-10-21 |
| DE3881472D1 (de) | 1993-07-08 |
| ATE90089T1 (de) | 1993-06-15 |
| GB8724912D0 (en) | 1987-11-25 |
| IL88122A0 (en) | 1989-06-30 |
| DE3881472T2 (de) | 1993-12-16 |
| CN1035113A (zh) | 1989-08-30 |
| ES2054825T3 (es) | 1994-08-16 |
| DK586588A (da) | 1989-04-24 |
| HUT50163A (en) | 1989-12-28 |
| EP0313397A1 (fr) | 1989-04-26 |
| FI884879A7 (fi) | 1989-04-24 |
| HU202230B (en) | 1991-02-28 |
| ZA887900B (en) | 1990-06-27 |
| PT88829B (pt) | 1993-01-29 |
| PL158305B1 (en) | 1992-08-31 |
| JP2501631B2 (ja) | 1996-05-29 |
| JPH01146882A (ja) | 1989-06-08 |
| DK586588D0 (da) | 1988-10-21 |
| MC1983A1 (fr) | 1989-11-23 |
| AU604165B2 (en) | 1990-12-06 |
| PL275423A1 (en) | 1989-08-07 |
| AU2418188A (en) | 1989-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD283140A5 (de) | Verfahren zur herstellung von therapeutischen heterozyclischen verbindungen | |
| DE69127260T2 (de) | Therapeutische heterocyclische verbindungen | |
| DE69227458T2 (de) | Tryptamin analoga, ihre herstellung und anwendung als 5-ht1-artige rezeptoren oder 5-ht2 rezeptor agonisten | |
| DE69620241T2 (de) | Gonadotropin releasing hormon- antagonisten | |
| DE69522718T2 (de) | Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren | |
| DE3527648C2 (fr) | ||
| DE3131748C2 (fr) | ||
| DE60002554T2 (de) | Pyrazino(aza)indolderivate | |
| EP0708101B1 (fr) | Dérivés de pipéridine utiles comme antagonistes des récepteurs des neurokinines | |
| DE69132450T2 (de) | Serotonin 5HT1A und 5HT1D Agonisten | |
| EP0700905B1 (fr) | Dérivés tricycliques de pyrazole | |
| DE60211199T2 (de) | 3-substituierte oxindol-beta-3-agonisten | |
| DE3008632A1 (de) | Indol-derivate, verfahren zu ihrer herstellung und ihre verwendung | |
| DE60113563T2 (de) | Substituierte 2-phenylaminoimidazolin-phenyl-ketonderivate als ip-antagonisten | |
| DE69016530T2 (de) | 1,3-Dihydro-1-(pyridinylamino)-2H-indol-2-one, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel. | |
| FR2722190A1 (fr) | Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant | |
| HU223973B1 (hu) | Indazol-karboxamid-származékok, előállításuk és a vegyületeket tartalmazó gyógyászati készítmények | |
| EP0740658B1 (fr) | Derives n-substitues d'azabicycloheptane utilises, par exemple, comme neuroleptiques | |
| DE69300373T2 (de) | (1H-Indol-1-yl)-2-(Amino)Acetamide und verwandte (1H-Indol-1-yl)-(Aminoalkyl)Amide, Zwischenprodukte, Verfahren zur Herstellung davon und ihre Verwendung als Arzneimittel. | |
| JPH09510706A (ja) | ドパミン作動性活性を有するベンゾイミダゾール誘導体 | |
| DE3700407A1 (de) | Indolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen | |
| WO1997034874A1 (fr) | Derives trisubstitues 1,3,5 de l'indazole a action antiasthmatique, antiallergique, anti-inflammatoire et immunomodulatrice | |
| WO2009118163A1 (fr) | Dérivés de (hétéro-)aryl-cyclohexane | |
| DE69529790T2 (de) | Imidazolin-Derivate, deren Herstellung und deren Verwendung als Tachykinin-Rezeptor Antagonisten | |
| US5225431A (en) | Therapeutic substituted indole compounds and compositions thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |